Jo Pearsall

As a graduate of the University of Kent (Eliot 1989, History) Jo was very happy to come back to the University as a member of staff, originally as a part-time member of the Congregations Office. Jo was the University’s Congregations and Events Manager for about five years and fondly remembers seeing many Kent students graduate in both Canterbury and Rochester Cathedrals.

Jo later moved to the Central Secretariat, learning a great deal about the University and developing her role, which led to her appointment as Student Conduct and Complaints Officer in Student Services in 2013. In April 2014 Jo returned to the Central Secretariat as Deputy Secretary of the Council. Jo’s involvement in the University’s many and varied musical activities began when she was a  (Read more...)

Tonbridge

For over 25 years, the University’s Tonbridge Centre has offered opportunities for both academic study and career progression, as well as bespoke training for local business and government communities.

Our facilities are situated in Tonbridge town centre, a few minutes' walk from the high street and Tonbridge railway station.

A vast array of engaging short courses and study days are available

at the Tonbridge Centre. They allow students who enrol on them to explore a subject purely for interest, among like-minded people, without formal assessment. Flexible study options are available each term across subjects such as: art history, creative writing, geology, history, literature, music, psychology, conservation, and politics.

The Centre is (Read more...)

Biopharmaceutical proteins

The use of pharmaceutical drugs produced in living cells has been steadily rising, with many of the most common biopharmaceuticals being proteins. Research to improve the production and secretion of these protein drugs by cells has become a crucial part of drug discovery and development.

The patented technology developed

by Kent’s Robert Freedman and Mick Tuite in collaboration with the US pharmaceutical company Merck, can produce increases in the levels and authenticity of a range of high-value, secretory proteins. Several major pharmaceutical companies including Novozymes and Pfizer are using the technology to help develop and produce drugs for treating a wide range of human diseases, such as type 2 diabetes.